More U.S. adults believe it is a good thing than a bad thing for adults to use weight-loss drugs like Ozempic, Wegovy and other brands ...
BMI is a widely used tool for assessing obesity, but it has limitations. It doesn't account for muscle mass, fat distribution or bone density. Experts suggest using it alongside other measures for ...
The percentage of U.S. adults with obesity did not significantly rise from 2013 to 2023, though a small uptick in the rate of ...
Research has uncovered key differences in gene expression linked to inflammation, metabolism and cardioprotection. These findings could help inform the development of targeted therapies for ...
New CDC data reveals a concerning rise in severe obesity among U.S. adults, with women and middle-aged individuals most affected. The obesity epidemic continues to strain the healthcare system with ...
Coming soon: Drugs for weight loss have been used for a long time in practice, however recent developments prompted the need for this special edition. The goals of this collection are to discuss ...
As many as 40% of Americans are obese, putting them at an increased risk for high blood pressure, diabetes, stroke, heart ...
Related U.S. influenza cases reach 15-year high despite declining COVID-19, CDC says Flossing regularly can help prevent strokes, study says Report: Obesity, diabetes, high blood pressure remain ...
A pet cat was announced infected with the H5N1 bird flu shortly after the CDC released data suggesting an adolescent may have caught the virus from a cat. (Associated Press) ...
Your insights and observations are appreciated. … The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential ...
LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed ...
Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial on a clinical hold, the company announced Feb. 4. Amgen has not detailed ...